SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has announced the initiation of a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide designed to treat obesity and type 2 diabetes. This program is aligned with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, a necessary step before first-in-human clinical trials.
The announcement marks a significant transition for SureNano, which is positioning itself as an agile entrant in the rapidly expanding GLP-1 market. The company has developed a patented second-generation incretin-based therapy after securing licensing rights to the GEP-44 compound from Syracuse University. According to the press release, the GLP toxicology and pharmacology studies are designed to de-risk the lead candidate and support the strategy of launching a Phase I clinical trial in Australia.
Dr. Nihar Pandey, Chief Scientific Officer at SureNano, emphasized the importance of this milestone. “Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic,” said Dr. Pandey. “Partnering with a globally renowned CRO like LabCorp will ensure our studies meet the highest regulatory standards. This package is vital to de-risk our lead candidate and is designed to support our strategy of launching a Phase I clinical trial in Australia.”
The implications of this development are significant for the obesity and diabetes treatment landscape. GLP-1 receptor agonists have become a multi-billion dollar market, with drugs like semaglutide (Ozempic, Wegovy) showing high demand. SureNano's GEP-44 aims to differentiate itself with improved tolerability and potential non-injectable delivery, which could address common barriers to patient adherence. The ongoing GLP studies are critical to establishing safety and efficacy data required for regulatory approval.
SureNano Science is transitioning from its initial business of selling the SureNano surfactant to becoming a pharmaceutical-focused company. The company acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company, to advance GEP-44. The surfactant business, which provides a base for nanoemulsions, continues to operate under exclusive licenses in Canada, Oklahoma, and Colorado.
For investors, the progression to IND-enabling studies represents a key value inflection point. Success in these preclinical studies could pave the way for clinical trials and eventual commercialization. The company's focus on obesity and metabolic disease targets a global health crisis affecting hundreds of millions of people. The full article is available at https://ibn.fm/78hI3.
More information about SureNano Science can be found in the company's newsroom at https://ibn.fm/SURNF.
